Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review

Background Non-small-cell lung cancer (NSCLC) accounts for most new diagnoses of lung cancer, with high morbidity and mortality worldwide. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of metastatic and advanced NSCLC. For resectable NSCLC, while surgery is the cornerstone...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2021-07, Vol.16 (4), p.425-434
Hauptverfasser:	Zhao, Ziran, Gao, Yibo, Xue, Qi, Gao, Shugeng, He, Jie
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Biomedicine Cancer research Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Clinical trials Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Life Sciences & Biomedicine Lung cancer Lung Neoplasms - drug therapy Medicine Medicine & Public Health Oncology Science & Technology Surgical outcomes Systematic Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!